Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Observational 2Interventional 2Expanded_access 1

Sponsor

Conditions

Breast Neoplasms 10180Neoplasms 7807Carcinoma, Non-Small-Cell Lung 5756Prostatic Neoplasms 5024Colorectal Neoplasms 4603Lung Neoplasms 3723Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3082Multiple Myeloma 3081Pancreatic Neoplasms 2843Melanoma 2651Ovarian Neoplasms 2573Lymphoma 2570Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Recurrence 2229Head and Neck Neoplasms 2102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia 2013Brain Neoplasms 1902Glioblastoma 1795Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1719Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Miransertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Proteus Syndrome × Clear all
NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

NCT02594215 2022-06-30

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
6 enrolled

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡